AVON, Conn., Jan. 19, 2012 /PRNewswire/ -- The Specialty Photonics Division of OFS Fitel, LLC (OFS SPD), a leading provider of optical fiber, cable, and assemblies for medical device manufacturers, announces that Dr. Andrei Stolov will present "Optical fibers with polyimide coatings for medical applications" at the upcoming BiOS Technology Conference. Dr. Stolov will present on Sunday, January 22nd at 12:10 PM, in room 206 (Mezzanine).
(Logo: http://photos.prnewswire.com/prnh/20120119/CL38819LOGO )
The focus of the work was to model extreme conditions that optical fibers may encounter in medical applications. Three commercially available fibers were examined. A battery of tests were completed analyzing how well each fiber withstood exposure to extreme heat and humidity, multiple autoclave cycles, extended water soak, and immersion in organic solvents. Key properties of polyimide-coated optical fibers, un-aged and exposed to various harsh environments, were investigated. Dr. Stolov commented that "The results of the work will certainly be of interest to engineers who are either evaluating or thinking of evaluating polyimide-coated fibers for their medical application."
OFS SPD will exhibit and showcase its line of optical fiber, cable, and assemblies for the medical market at the BiOS Tradeshow, January 21st-22nd.
OFS is a world-leading designer, manufacturer and provider of optical fiber, optical fiber cable, FTTX, optical connectivity and specialty photonics products. Our manufacturing and research divisions work together to provide innovative products and solutions that traverse many different applications as they link people and machines worldwide. Between continents, between cities, around neighborhoods, and into homes and businesses of digital consumers we provide the right optical fiber, optical cable and components for efficient, cost-effective transmission.
OFS' corporate lineage dates back to 1876 and includes technology powerhouses such as AT&T and Lucent Technologies (now Alcatel-Lucent. Today, OFS is owned by Furukawa Electric, a multi-billion dollar global leader in optical communications.
Headquartered in Norcross (near Atlanta) Georgia, U.S., OFS is a global provider with facilities in Avon, Connecticut; Carrollton, Georgia; Somerset, New Jersey; and Sturbridge, Massachusetts, as well as in Denmark, Germany and Russia. For more information, please visit www.ofsoptics.com.
About OFS, Specialty Photonics Division
OFS, Specialty Photonics Division, is an industry leader in optical fiber design or modification for highly specialized or customized applications. It supplies advanced optical fibers, including specialty multimode, specialty single-mode, rare-earth doped, polarization-maintaining and other nonstandard fibers. It also manufactures specialty cables and connectors, and other specialty products, such as high-power laser components. For more information about the Specialty Photonics Division, please visit: www.SpecialtyPhotonics.com
Related medicine technology :1
|SOURCE OFS, Specialty Photonics Division|
Copyright©2010 PR Newswire.
All rights reserved
. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA2
. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate3
. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference4
. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)5
. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference6
. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 20077
. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference8
. Iomai Announces Data from Phase 2 Field Study of Travelers Diarrhea Vaccine Accepted for Presentation at ICAAC9
. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer10
. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia11
. ViroPharma to Present at Three Upcoming Healthcare Conferences